The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
Danielle M Dunlea, Laura T Fee, Thomas McEnery, Noel G McElvaney, Emer P Reeves Irish Centre for Genetic Lung Disease, Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland Abstract: Alpha-1 antitrypsin (AAT) is the most abundant serine protease inhibitor c...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-03-01
|
| Series: | Journal of Inflammation Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-impact-of-alpha-1-antitrypsin-augmentation-therapy-on-neutrophil-d-peer-reviewed-article-JIR |
| _version_ | 1818733853456465920 |
|---|---|
| author | Dunlea DM Fee LT McEnery T McElvaney NG Reeves EP |
| author_facet | Dunlea DM Fee LT McEnery T McElvaney NG Reeves EP |
| author_sort | Dunlea DM |
| collection | DOAJ |
| description | Danielle M Dunlea, Laura T Fee, Thomas McEnery, Noel G McElvaney, Emer P Reeves Irish Centre for Genetic Lung Disease, Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland Abstract: Alpha-1 antitrypsin (AAT) is the most abundant serine protease inhibitor circulating in the blood. AAT deficiency (AATD) is an autosomal codominant condition affecting an estimated 3.4 million individuals worldwide. The clinical disease associated with AATD can present in a number of ways including COPD, liver disease, panniculitis and antineutrophil cytoplasmic antibody vasculitis. AATD is the only proven genetic risk factor for the development of COPD, and deficient individuals who smoke are disposed to more aggressive disease. Principally, AAT is a serine protease inhibitor; however, over the past number of years, the assessment of AAT as simply an antiprotease has evolved, and it is now recognized that AAT has significant anti-inflammatory properties affecting a wide range of cells, including the circulating neutrophil. Keywords: neutrophils, alpha-1 antitrypsin deficiency, alpha-1 antitrypsin augmentation, inflammation, airways disease |
| first_indexed | 2024-12-17T23:56:04Z |
| format | Article |
| id | doaj.art-f1620ab2eb794c16b3c4e4484422dd48 |
| institution | Directory Open Access Journal |
| issn | 1178-7031 |
| language | English |
| last_indexed | 2024-12-17T23:56:04Z |
| publishDate | 2018-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Inflammation Research |
| spelling | doaj.art-f1620ab2eb794c16b3c4e4484422dd482022-12-21T21:28:03ZengDove Medical PressJournal of Inflammation Research1178-70312018-03-01Volume 1112313437431The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individualsDunlea DMFee LTMcEnery TMcElvaney NGReeves EPDanielle M Dunlea, Laura T Fee, Thomas McEnery, Noel G McElvaney, Emer P Reeves Irish Centre for Genetic Lung Disease, Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland Abstract: Alpha-1 antitrypsin (AAT) is the most abundant serine protease inhibitor circulating in the blood. AAT deficiency (AATD) is an autosomal codominant condition affecting an estimated 3.4 million individuals worldwide. The clinical disease associated with AATD can present in a number of ways including COPD, liver disease, panniculitis and antineutrophil cytoplasmic antibody vasculitis. AATD is the only proven genetic risk factor for the development of COPD, and deficient individuals who smoke are disposed to more aggressive disease. Principally, AAT is a serine protease inhibitor; however, over the past number of years, the assessment of AAT as simply an antiprotease has evolved, and it is now recognized that AAT has significant anti-inflammatory properties affecting a wide range of cells, including the circulating neutrophil. Keywords: neutrophils, alpha-1 antitrypsin deficiency, alpha-1 antitrypsin augmentation, inflammation, airways diseasehttps://www.dovepress.com/the-impact-of-alpha-1-antitrypsin-augmentation-therapy-on-neutrophil-d-peer-reviewed-article-JIRNeutrophilsalpha-1 antitrypsin deficiencyalpha-1 antitrypsin augmentationinflammationairways disease |
| spellingShingle | Dunlea DM Fee LT McEnery T McElvaney NG Reeves EP The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals Journal of Inflammation Research Neutrophils alpha-1 antitrypsin deficiency alpha-1 antitrypsin augmentation inflammation airways disease |
| title | The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals |
| title_full | The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals |
| title_fullStr | The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals |
| title_full_unstemmed | The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals |
| title_short | The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals |
| title_sort | impact of alpha 1 antitrypsin augmentation therapy on neutrophil driven respiratory disease in deficient individuals |
| topic | Neutrophils alpha-1 antitrypsin deficiency alpha-1 antitrypsin augmentation inflammation airways disease |
| url | https://www.dovepress.com/the-impact-of-alpha-1-antitrypsin-augmentation-therapy-on-neutrophil-d-peer-reviewed-article-JIR |
| work_keys_str_mv | AT dunleadm theimpactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals AT feelt theimpactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals AT mceneryt theimpactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals AT mcelvaneyng theimpactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals AT reevesep theimpactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals AT dunleadm impactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals AT feelt impactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals AT mceneryt impactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals AT mcelvaneyng impactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals AT reevesep impactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals |